[Source: NewsWire] – Cyplasin Biomedical, a specialty pharmaceutical company focused on hepatitis prevention and anti-viral therapies, has signed an agreement effective December 29, 2009 which transfers an exclusive worldwide license for a patented hepatitis C viral vaccine and other technology/know-how to Cyplasin. The technology had originally been licensed from the National Institutes of Health (NIH) by Virionics Corporation, a Scottsdale, Arizona-based biotech company.
For more inforamation: Cyplasin Announces Hepatitis C License Assignment from Virionics Corporation